Related Experiment Video

Updated: May 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Promise of factor Xa inhibition in atrial fibrillation

Sana M Al-Khatib1, John H Alexander, Renato D Lopes

  • 1Division of Cardiology, Department of Medicine, Duke Clinical Research Institute and Duke University, 2400 Pratt Street, PO Box 17969, Durham, NC 27705, USA. alkha001@mc.duke.edu

Current Cardiology Reports
|November 24, 2011
PubMed

Insights

Warfarin prevents stroke in atrial fibrillation patients but is underused. New anticoagulants, especially factor Xa inhibitors, offer alternatives with emerging trial data on efficacy and safety.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Warfarin is proven effective for stroke prevention in atrial fibrillation (AF).
  • Clinical guidelines recommend warfarin for moderate to high-risk AF patients.
  • Warfarin underutilization persists due to its complexities.

Purpose of the Study:

  • To review anticoagulation complexities in AF.
  • To highlight challenges of warfarin therapy.
  • To overview novel anticoagulants, focusing on factor Xa inhibitors in AF.

Main Methods:

  • Review of randomized clinical trials (RCTs) and practice guidelines.
  • Analysis of challenges associated with warfarin.
  • Synthesis of data on new oral anticoagulants (NOACs), particularly factor Xa inhibitors.

Main Results:

  • RCTs confirm warfarin's efficacy in AF stroke prevention.
  • Despite guidelines, warfarin use is suboptimal.
  • Newer anticoagulants, including factor Xa inhibitors, are emerging as alternatives.

Conclusions:

  • Complexities of warfarin contribute to its underutilization.
  • Factor Xa inhibitors represent a significant advancement in AF anticoagulation.
  • Emerging RCT data support the efficacy and safety of novel anticoagulants in AF management.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.